Inclusion Criteria:  ≥ 21 years of age Be able to provide written informed consent Current or potential hypoproliferative thrombocytopenia with expected platelet count of <20 X 109/L for a minimum of 5 days in a 28-day period If pre-menopausal female of child bearing potential, then the subject must have a negative serum pregnancy test prior to study commencement, and must be using an acceptable method of contraception during the study. Calculated creatinine clearance of >30 ml/min (as calculated based on the Cockcroft-Gault equation; National Kidney Foundation 2017) at the point of recruitment, and within one week before transfusion  Exclusion Criteria:  Not meeting the inclusion criteria specified above Pregnant Breastfeeding Current platelet refractoriness History of allergy or adverse reaction to DMSO History of veno-occlusive disease History of acute venous or arterial thromboembolism within the last 3 months. History of unprovoked venous thromboembolism On antiplatelets, NSAIDs or anticoagulants within 1 week, and TCM (traditional Chinese medicine) which are known to decrease platelet count or platelet function or increase bleeding tendency within 2 weeks of study enrolment. Received or will be receiving L-asparaginase chemotherapy within 7 days of platelet transfusion Renal impairment with calculated creatinine clearance of <30ml/min. Non-cutaneous Grade 2 and above bleeding at the time of study assessment Presently with or a history of acute promyelocytic leukemia (APML), immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), haemolytic-uremic syndrome (HUS), or any thrombotic microangiopathy (TMA) Presently with or a history of heparin-induced thrombocytopenia Presently with disseminated intravascular coagulation (DIC) or other risk factor(s) for bleeding other than thrombocytopenia (including platelet dysfunction, PT ≥ 1.3 X upper limit of normal for the laboratory, PTT ≥ 1.3 X upper limit of normal for the laboratory, or fibrinogen ≤ 1 g/L) History of anaphylaxis from blood transfusion Involved in any other therapeutic clinical trials in the last 6 months prior to the start of this research Concomitant participation in other therapeutic clinical trials during the full period of this study Receiving non-trial-related medication that might compromise transfusion safety Known history of congenital bleeding disorder Subject who declined to consent for platelet transfusion